Clinical Trial: Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
Study Status: Completed
Recruit Status: RECRUITING
Condition: Waldenstrom Macroglobulinemia
Study Type: INTERVENTIONAL
Official Title: A Phase II Study Evaluating Venetoclax and Pirtobrutinib in Previously Treated Waldenström Macroglobulinemia
Brief Summary:
This study is being done to examine the safety and effectiveness of pirtobrutinib combined with venetoclax as a possible treatment for participants with Waldenström Macroglobulinemia (WM).The names of the study drugs involved in this study are:Pirtobrutinib (a Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor)Venetoclax (a BCL2 inhibitor)
Read more